Financing ·
CalciMedica, Inc. entered into a securities purchase agreement for a private placement of 18,673,429 units at a…
CALCCalciMedica, Inc.
CalciMedica, Inc. entered into a securities purchase agreement for a private placement of 18,673,429 units at a purchase price of approximately $0.80 per unit, expected to raise up to $15 million in gross proceeds and up to $34 million in additional proceeds from warrant exercises. The company plans to use the funds to advance its pulmonary hypertension strategy and fund research and development. CalciMedica, Inc. is a biotechnology company focused on developing CRAC channel inhibitors for various diseases.